INS and metabolic dysfunction-associated steatotic liver disease: Experimental evidence has indicated that VSL#3 could attenuate inflammation via modulation of the nuclear factor-kB (NF-kB) pathway [92], reduce hepatic fat accumulation and ALT levels [93], improve insulin sensitivity in NAFLD models [94], and prevent against liver fibrosis in NASH patients [95].